Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | RGS12 | O14924 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22050093 | 0.83 | HTR6 (0.32) | HTR6 | |
| SCHEMBL7875449 | 0.79 | TSHR (0.35) | HTR6RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL13531056 | 0.79 | TSHR (0.35) | HTR6RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL20803989 | 0.78 | SIGMAR1 (0.35) | HTR6RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL14155139 | 0.77 | SIGMAR1 (0.30) | — | |
| SCHEMBL8973166 | 0.75 | OPRM1 (0.39) | GPR84OPRM1TSHRSPHK1 | |
| SCHEMBL8973592 | 0.75 | OPRM1 (0.39) | GPR84OPRM1TSHRSPHK1 | |
| SCHEMBL8973370 | 0.75 | OPRM1 (0.39) | GPR84OPRM1TSHRSPHK1 | |
| SCHEMBL8458912 | 0.67 | — | — | |
| SCHEMBL20215763 | 0.67 | TSHR (0.37) | HTR6RGS12CYP3A4TSHRGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | GPR84 1577/4885OPRM1 4146/4885HTR6 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.